LadRx (NASDAQ:CYTR) Receives New Coverage from Analysts at StockNews.com

Equities research analysts at StockNews.com initiated coverage on shares of LadRx (NASDAQ:CYTR – Get Rating) in a note issued to investors on Tuesday. The firm set a “hold” rating on the stock.

LadRx Price Performance

Shares of NASDAQ CYTR opened at $0.09 on Tuesday. The firm has a fifty day moving average of $0.10 and a 200 day moving average of $0.12. LadRx has a one year low of $0.05 and a one year high of $0.86.

LadRx Company Profile

(Get Rating)

LadRx Corp. is a biopharmaceutical research and development company, which engages in the discovery, research, and clinical development of novel anti-cancer drug candidates. It focuses on developing the Linker Activated Drug Release (LADR) technology platform, a discovery engine to help create a pipeline of anti-cancer molecules that will avoid unacceptable systemic toxicity while delivering highly potent agents directly to the tumor.